[The demonstration of hepatitis B virus DNA with the polymerase chain reaction].

Dtsch Med Wochenschr

Privates Institut für Immunologie und Molekulargenetik GmbH, Karlsruhe.

Published: August 1990

Results with the polymerase chain reaction and conventional DNA hybridizing technique (dot-blot) for the detection of hepatitis B virus (HBV) DNA were compared for 439 patients. In 261 patients who were positive for HBs antigen (Ag), HBV DNA was demonstrated with the polymerase reaction in all of the 69 HBe-Ag positive sera (dot-blot 56%), as well as in 81 (62%) of 131 anti-HBe positive sera (dot-blot 5%), in 29 (48%) of 61 HBe marker negatives (dot-blot 3%) and in six (29%) of 21 delta positive sera. Among HBs-Ag negative patients, HBV DNA was detected in six (22%) of 27 anti-HBc positive sera, but not in sera (n = 50) which were both anti-HBc and anti-HBs positive, as well as in HBV marker negative patients with liver disease (n = 30) and healthy controls (n = 50). If infectiousness is to be checked or in case of double infection, the more sensitive polymerase chain reaction is to be recommended for the detection of HBV DNA. HBe-Ag positive patients must be considered as infectious: tests for HBV DNA can in general be omitted.

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-2008-1065158DOI Listing

Publication Analysis

Top Keywords

hbv dna
20
positive sera
16
polymerase chain
12
hepatitis virus
8
chain reaction
8
hbe-ag positive
8
sera dot-blot
8
negative patients
8
dna
7
positive
7

Similar Publications

A Cell-penetrating bispecific antibody suppresses hepatitis B virus replication and secretion.

Virus Res

January 2025

Medical Research Center, Yuebei People's Hospital, Shantou University Medical College, 512025, Shaoguan, China; Shenzhen Immuthy Biotech Co., Ltd, 518107, Shenzhen, Guangdong, China. Electronic address:

Hepatitis B virus (HBV) represents one of the major pathogenic factor that leads to chronic liver diseases and the development of hepatocellular carcinoma (HCC). The currently approved anti-HBV drugs cannot eradicate the virus or block the development of HCC. HBV nucleocapsid consists of the hepatitis B core antigen (HBcAg) and the HBV relaxed-circular partially double-stranded DNA (rcDNA), indispensable in virus replication.

View Article and Find Full Text PDF

Hepatitis B virus (HBV) is a major public health concern responsible for hepatitis and hepatocellular carcinoma (HCC) worldwide. In Mozambique, HBsAg prevalence is high and endemic, and despite the strategies to mitigate the spread of the disease, the HCC incidence is still high and one of the highest in the world. There is still limited data on the serological profile and molecular epidemiology of HBV in Mozambique given the burden of this disease.

View Article and Find Full Text PDF

In the 1980s, Poland was a medium-endemic country, with one of the highest incidences of hepatitis B in Europe (45/10 inhabitants). Pursuant to the WHO guidelines, obligatory vaccination was introduced in 1994-1996 (as a part of hepatitis B prophylaxis for newborns), and in 2000-2011, all 14-year-olds were vaccinated. To prevent transfusion-transmitted HBV infection (TT-HBV), since the 1970s, each donation has been tested for HBsAg and, since 2005, additionally for the presence of HBV DNA.

View Article and Find Full Text PDF

Information on circulating HBV (sub-)genotype, variants, and hepatitis D virus (HDV) coinfection, which vary by geographical area, is crucial for the efficient control and management of HBV. We investigated the genomic characteristics of HBV (with a prevalence of 8.1%) and the prevalence of HDV in Nigeria.

View Article and Find Full Text PDF

Surveillance Following Hepatitis B Surface Antigen Loss: An Issue Requiring Attention.

Pathogens

December 2024

Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan 430030, China.

Due to the lack of agents that directly target covalently closed circular DNA and integrated HBV DNA in hepatocytes, achieving a complete cure for chronic hepatitis B (CHB) remains challenging. The latest guidelines recommend (hepatitis B surface antigen) HBsAg loss as the ideal treatment target for improving liver function, histopathology, and long-term prognosis. However, even after HBsAg loss, hepatitis B virus can persist, with a risk of recurrence, reactivation, cirrhosis, and hepatocellular carcinoma.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!